




RealRate

PHARMACEUTICAL 2020

Intra-Cellular Therapies Inc.
Rank 224 of 362



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



RealRate

PHARMACEUTICAL 2020

Intra-Cellular Therapies Inc. Rank 224 of 362



The relative strengths and weaknesses of Intra-Cellular Therapies Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Intra-Cellular Therapies Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 179% points. The greatest weakness of Intra-Cellular Therapies Inc. is the variable Net Income, reducing the Economic Capital Ratio by 140% points.

The company's Economic Capital Ratio, given in the ranking table, is -250%, being 53% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	230,324
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	36,224
Liabilities, Non-Current	19,955
Other Assets	18,603
Other Compr. Net Income	796
Other Expenses	1.6
Other Liabilities	0
Other Net Income	6,291
Property and Equipment	2,260
Research and Development	89,125
Revenues	61
Selling, General and Administrative Expense	64,948

Output Variable	Value in 1000 USD
Assets	251,186
Liabilities	56,179
Expenses	154,074
Stockholders Equity	195,007
Net Income	-147,722
Comprehensive Net Income	-147,324
Economic Capital Ratio	-250%



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai